JLR: Virtual issue sheds light on a key risk factor for heart disease
Because lipids such as cholesterol and triglycerides are hydrophobic and tend to clump up, rather than dissolve, in water, they need help getting around inside the body. Lipoproteins are complex assemblies with hydrophilic outer shells that package hydrophobic lipids in their core, allowing them to hitch a ride through the bloodstream. These delivery particles play an important role in the absorption of dietary lipids from the small intestine and also transport lipids to and from the liver.

High levels of one particular class of lipoprotein, known as lipoprotein (a), are associated with atherosclerosis, inflammation and thrombosis, but no treatments are available in the clinic that specifically lower Lp(a), and much of what governs Lp(a) assembly is still unknown.
A new from the Journal of Lipid Research titled “Lipoprotein (a): Many strides made, yet there is a long road ahead” explores the past, present and future status of Lp(a) research and showcases researchers pushing this field forward. This issue was assembled by JLR Junior Associate Editor from Columbia University Irving Medical Center in New York City.
Several papers collected in this issue offer insights into how various Lp(a)-reducing drugs work. In one of these studies, and colleagues at the University of California, Davis, and the University of Hong Kong demonstrated that alirocumab — an inhibitor of the lipid-binding enzyme PCSK9 — could lower Lp(a) levels regardless of the isoform of proteins in Lp(a).
A study by and an international team of researchers suggests that another PCSK9 inhibitor, evolocumab, reduces Lp(a) levels partly by increasing the expression of LDL receptors.
Elisa Waldmann and at Ludwig Maximilian University of Munich wrote a review that discusses apheresis as an effective method of selectively clearing Lp(a) from the blood and reducing risk of cardiovascular disease.
Another review, penned by at McGill University, describes the association of Lp(a) with aortic valve disease and outlines steps toward developing much-needed preventive and therapeutic strategies.
Enjoy reading 91亚色传媒 Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91亚色传媒 Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Targeting toxins to treat whooping cough
Scientists find that liver protein inhibits of pertussis toxin, offering a potential new treatment for bacterial respiratory disease. Read more about this recent study from the Journal of Biological Chemistry.

Elusive zebrafish enzyme in lipid secretion
Scientists discover that triacylglycerol synthesis enzyme drives lipoproteins secretion rather than lipid droplet storage. Read more about this recent study from the Journal of Biological Chemistry.

Scientists identify pan-cancer biomarkers
Researchers analyze protein and RNA data across 13 cancer types to find similarities that could improve cancer staging, prognosis and treatment strategies. Read about this recent article published in Molecular & Cellular Proteomics.

New mass spectrometry tool accurately identifies bacteria
Scientists develop a software tool to categorize microbe species and antibiotic resistance markers to aid clinical and environmental research. Read about this recent article published in Molecular & Cellular Proteomics.

New tool matches microbial and metabolic metaproteomic data
Scientists develop a bioinformatics program that maps omics data to metabolic pathways. Read about this recent article published in Molecular & Cellular Proteomics

Meet Paul Shapiro
Learn how the JBC associate editor went from milking cows on a dairy farm to analyzing kinases in the lab.